Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Kura Oncology (Nasdaq: KURA) announced that on November 3, 2025 its Compensation Committee granted inducement nonstatutory stock options to a new non-executive employee under the company's 2023 Inducement Option Plan, as amended.

The grant totals 21,750 options with an exercise price of $9.77 per share (the closing price on November 3, 2025). Options vest over four years: 25% at one year then monthly over the following 36 months, subject to continued service, and are governed by the plan and a stock option agreement. The committee approved the award as an inducement in accordance with Nasdaq Listing Rule 5635(c)(4).

News Market Reaction

-2.95%

1 alert

-2.95% News Effect

On the day this news was published, KURA declined 2.95%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

SAN DIEGO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on November 3, 2025, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 21,750 shares of common stock to a new non-executive employee under the Company’s 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employee’s employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Each stock option has an exercise price equal to $9.77 per share, the closing price of the Company’s common stock on November 3, 2025, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employee’s continued service relationship with the Company through the applicable vesting dates. The stock options are subject to the terms and conditions of the Company’s 2023 Inducement Option Plan, as amended, and the terms and conditions of an applicable stock option agreement covering the grant.

About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura is developing ziftomenib, a menin inhibitor targeting certain genetic drivers of acute myeloid leukemias, and continues to pioneer advancements in both menin inhibition and farnesyl transferase inhibition to address mechanisms of adaptive and innate resistance in the treatment of solid tumors. For additional information, please visit the Kura website at https://kuraoncology.com/ and follow us on X and LinkedIn.

Contacts        

Investors and media:
Greg Mann
858-987-4046
gmann@kuraoncology.com

FAQ

What did Kura Oncology announce on November 7, 2025 regarding inducement grants (KURA)?

Kura announced that on November 3, 2025 it granted 21,750 inducement stock options to a new non-executive employee under its 2023 Inducement Option Plan.

What is the exercise price and vesting schedule for the KURA inducement options?

The options have an exercise price of $9.77 per share and vest over four years: 25% at one year then monthly over 36 months, subject to continued service.

How does the KURA inducement grant comply with Nasdaq rules?

The Compensation Committee approved the grant as an inducement material to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Under which plan were the KURA inducement options granted?

The options were granted under the company's 2023 Inducement Option Plan, as amended, and are subject to the plan and a stock option agreement.

Will the KURA inducement options immediately dilute existing shareholders?

The announcement discloses 21,750 options with an exercise price but does not state immediate dilution or the company's total shares outstanding.